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Atherosclerosis is a systemic process, and the leading cause of morbidity and mortality in the developed world. HMG-CoA
reductase inhibitors (‘statins’) are potent lipid lowering drugs, which have been shown to reduce morbidity and mortality
in patients with coronary atherosclerosis. Objective: To present the up-to-date data concerning statin use in the prevention
and treatment of extra-coronary atherosclerosis. Methods: Clinical trials with statins in patients with extra-coronary
atherosclerosis were searched for via PUBMED. Findings and conclusions: The different forms of peripheral arterial disease
(e.g. cerberovascular disease, lower extremity peripheral arterial disease) are associated with significant cardiovascular
morbidity and mortality, and hence constitute a coronary artery disease equivalent in terms of published practice guide-
lines. There is some evidence from small randomized controlled trials that statin therapy decreases cardiovascular morbid-
ity and mortality in patients with peripheral arterial disease. The mechanism of action of statins may derive from their lipid
lowering properties, or from other, pleiotropic effects. Further, larger randomized controlled studies with statins are needed
to evaluate the efficacy of statin therapy in patients with stable peripheral arterial disease and in those undergoing vascular
or endovascular surgery.
Keywords: Statins; Primary prevention; Peripheral arterial disease; Cerebrovascular disease.Atherosclerosis is the leading cause of morbidity and
mortality in the developed world. The most common
presentation is coronary artery disease (CAD), but
atherosclerosis is a systemic process, often involving
other vascular sites, such as the carotid arteries, the
aorta, the renal and mesenteric arteries and large pe-
ripheral arteries such as the iliac and femoral arteries.
The benefit of HMG-CoA reductase inhibitors
(‘statins’) in terms of reduction in cardiac morbidity
and mortality in high-risk patients has been proved
in numerous studies. However, the effect of statins
on extra-cardiac manifestations of atherosclerosis has
not been as extensively studied. The purpose of this
review is to present the up-to-date data concerning
statin use in the prevention and treatment of extra-
coronary atherosclerosis. We will focus on two major
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Cerebrovascular Disease
In contrast with CAD, an association between the in-
cidence of stroke and serum cholesterol levels has
not been found, with the exception of adults younger
than 45 years.1e3 However, stroke and transient ische-
mic attacks (TIAs) are presumed to be, at least in part,
the outcome of atherosclerosis of the cerebrovascular
bed. Therefore many statin studies have included
stroke as a secondary outcome in the analysis, since
stroke is an important cause of death and disability
in developed countries.
A meta-analysis of 26 statin studies,4 including
90 000 participants, has shown that statin therapy
results in a 21% relative risk reduction of fatal or non-
fatal stroke, as compared with placebo. These studies
have encompassed 7 different patient populations,
including patients with hypercholesterolemia, coro-
nary heart disease, hypertension, diabetes mellitus,rved.
193Statin Treatment in Peripheral Arterial Diseasenormocholesterolemia, the elderly and patients with
prior stroke or TIA. In a sub-group analysis, this
meta-analysis failed to showany benefit in theminority
of patients with prior stroke.
A randomized controlled trial5 was designed specif-
ically to findoutwhether treatmentwith 80 mg atorvas-
tatin in patients with a recent history of stroke or TIA,
but with no history of coronary heart disease, and
with low density lipoprotein cholesterol (LDL-C)
levels between 100 and 190 mg/dL (2.6e4.9 mmol/L),
resulted in less recurrent cerebrovascular events (fatal
or non-fatal stroke). This study found a significant
16% relative risk reduction in the atorvastatin group,
as compared with placebo. The absolute risk reduction
was 2.2% (95% confidence interval (CI) 0.2e4.2%). The
main benefit seemed to result from a reduction in the
incidence of fatal stroke. This effect was believed to be
an underestimation of the true benefit, since 7.5% of
the placebo group had actually started non-study statin
therapy during the study period, resulting in 78.1% net
difference in statin use between the groups.
The mechanism by which statin therapy reduces
cerebrovascular events is not known. The SPARCL
study investigators had assigned most of this effect
to a significant 53% reduction in LDL-C levels in the
atorvastatin group, although this is not necessarily
the case, and plasma LDL-C levels might serve as
a marker for statin treatment, with the actual benefit
resulting from pleiotropic effects (see below).6
Lower Extremity Peripheral Arterial Disease
Lower extremity peripheral arterial disease (LE-PAD)
affects 3e4% of adults 40 years old, and over 20% of
the elderly, 70 years and older.7,8 It is usually defined
as an ankle-brachial index (ABI) of less than 0.9 on
Doppler examination. In many cases, lower extremity
PAD is asymptomatic, but in others it may present as
intermittent claudication, leg pain at rest, or critical
limb ischemia. Accordingly, it may have minor to
life-threatening outcomes.
Three main issues are relevant for decision making
about statin treatment for patients with lower extrem-
ity PAD: 1. Secondary prevention of coronary heart
disease; 2. Treatment of lower extremity peripheral
arterial disease; and 3. Perioperative treatment of
patients with peripheral arterial disease.
1. Secondary prevention of coronary heart disease
in LE-PAD patients
The AHA/ACC has acknowledged LE-PAD to be
a CAD equivalent,9 and has instituted a class Irecommendation for statin treatment for all LE-PADpa-
tients, with a target LDL-C level of less than 100 mg/dL
(2.6 mmol/L).10 For patients with very high risk of is-
chemic events, a target LDL-C of less than 70 mg/dL
is recommended (class IIa recommendation).
A few trials have studied the secondary prevention
of CAD in patients with LE-PAD. Their results are
summarized in Table 1.
Schillinger et al.11 reported the results of a prospec-
tive non-randomized non-interventional trial, which
was designed to study the association between statin
treatment, inflammatory activity and cardiovascular
outcome of patients with severe LE-PAD. Statin users
tended to havemore baseline risk factors, and lower in-
flammatory activity, as assessed by serum biomarkers.
Statin users had a significantly reduced risk of death
(RR¼ 0.52, 95% CI 0.30e0.91, p ¼ 0.022) and of the cu-
mulative end-point of death or myocardial infarction
(RR¼ 0.48, 95% CI 0.29e0.79, p ¼ 0.004). However,
stratification for inflammatory activity (Hs-CRP below
or abovemedian of 0.42) resulted in no significant ben-
efit for patients with low Hs-CRP, as opposed to a 42%
significant reduction in risk of mortality in the high
Hs-CRP group (p ¼ 0.046). The authors conclude that
statin therapy decreased the risk for adverse cardiovas-
cular outcome in patients with severe LE-PAD, most
probably by an anti-inflammatory mechanism.
An 8-year observational study, reported by Feringa
et al.,7 showed similar results: statin use (as well as the
use of aspirin, beta blockers or ACE inhibitors) was
found to be independently associated with a reduced
incidence of long-term mortality (HR¼ 0.46, 95% CI
0.58e0.80, p< 0.001).
REGRESS was a study primarily designed to assess
the effect of two year treatment with 40 mg pravasta-
tin on the coronary lumen. A sub-study within
REGRESS used B-mode ultrasound to quantitate
the intima-media thickness (IMT) of the carotid and
femoral arteries, and aimed to compare changes in
the coronary lumen with changes in peripheral
IMT.12 This sub-study showed a significant effect of
pravastatin on clinical events: 79.8% of placebo allo-
cated patients were free of clinical events (myocardial
infarction, coronary death, revascularizaion, stroke or
TIA or any death) after two years, as compared with
90.1% of the pravastatin group (p ¼ 0.02). Pravastatin
also positively influenced the combined femoral and
carotid IMT. However, therewas only amild-moderate
correlation between the change in coronary lumen
measures and the change in peripheral IMT, and there
was no correlation in treatment effects between the
two vascular beds.
The Heart Protection Study13 was a randomized
placebo-controlled double-blind study designed toEur J Vasc Endovasc Surg Vol 33, February 2007
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.Eur J Vasc Endovasc Surg Vol 33, February 2007assess the long-term effects of lipid lowering by sim-
vastatin on vascular and non-vascular mortality and
morbidity, in several pre-defined high-risk groups of
patients. In patients with LE-PAD at baseline, there
was a 25% statistically significant reduction in the
rate of major vascular events (i.e. major coronary
event, stroke or any revascularization) for the simvas-
tatin group as compared with the placebo group. Of
note, the proportional risk reduction was not re-
stricted to patients with high baseline cholesterol or
triglyceride levels, and was similar in patients with
pre-treatment LDL-C levels below 116 mg/dL
(3 mmol/L). This reduction was believed to be an un-
der-estimation of the true benefit, since many of the
placebo-allocated group had actually started receiving
non-study statins during the study period.
Despite the above data, and although LE-PAD has
long been acknowledged as a CAD equivalent,
LE-PAD patients remain undertreated with respect to
atherosclerosis risk factor control.14e18 However, this
must not be the case. For example, Rehring et al.16
show that use of a pharmacist-managed, physician-
monitored algorithm for the treatment of LE-PAD in
an outpatient setting resulted in higher adherence to
published guidelines, and a higher percentage of
patients achieving target levels.
2. Treatment of lower extremity PAD
A beneficial effect of serum cholesterol reduction
on femoral atherosclerosis was first described by
Blankenhorn et al.,19 in the Cholesterol Lowering
Atherosclerosis Study (CLAS). This was a randomized
controlled angiographic trial of colestipol, niacin and
low fat diet versus placebo and higher-fat diet. Com-
puter estimated atherosclerosis was calculated follow-
ing femoral angiography at baseline and after two
years of follow-up. On average, the actively treated
group showed less progression in estimated athero-
sclerosis as compared with the placebo treated group.
However, since the prescribed diet also differed be-
tween groups, a clear-cut benefit for the pharmacolog-
ical therapy could not be proved.
Several small trials have shown that statin therapy
improves symptoms and function in patients with
lower extremity PAD. Their results are summarized
in Table 2.
A cross-sectional report of 641 patients, 392 with
LE-PAD (ABI< 0.9) and 249 without LE-PAD (ABI
between 0.9 and 1.5), described by McDermott et al.20
showed that statin users had better 6-minute walk per-
formance, faster walking velocity and a higher sum-
mary performance score than patients not receiving
195Statin Treatment in Peripheral Arterial DiseaseT
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.statins, despite the fact that statin users had, in gen-
eral, more risk factors for atherosclerosis. Adjustment
for CRP levels attenuated the associations, which re-
mained significant only for the summary performance
score, and borderline significant for walking velocity.
However, these differences were significant for LE-
PAD as well as non-LE-PAD patients.
A further report by the same group after 3 years of
follow-up in the same cohort21 suggests that yearly
functional decline is slower in LE-PAD patients who
receive statins, as compared with LE-PAD patients
with no statin treatment. This effect was not seen in
non-LE-PAD patients.
The first randomized controlled study to show that
statin treatment improves PAD outcomes was the 4S.22
This study randomized 4444men andwomen between
35 and 70 years of age, with plasma total cholesterol
levels of 5.5e8.0 mmol/L (213e310 mg/dL) to placebo
or 20e40 mg simvastatin daily, for a median follow up
period of 5.4 years. The patients were asked about
symptoms of intermittent claudication and were ex-
amined for carotid and femoral bruits at the beginning
of the study and on yearly follow-up. No objective
tests were undertaken for the diagnosis of LE-PAD.
At baseline, 123 of the 2223 placebo-allocated patients
and 130/2221 of simvastatin-allocated patients had
intermittent claudication.23 The risk of new or worsen-
ing intermittent claudication was reduced by 38% in
the active treatment group (RR¼ 0.62, 95% CI 0.44e
0.88, p ¼ 0.008).
A short report by Aronow et al.24 describes ran-
domization of 69 patients with LE-PAD and intermit-
tent claudication to 40 mg simvastatin or placebo. The
simvastatin treated patients had improved treadmill
exercise time until onset of intermittent claudication
in 6 months and in 12 months after initiation of
treatment.
Mondillo et al.25 have shown that 6-months’ treat-
ment with 40 mg simvastatin in patients with intermit-
tent claudication resulted in a significant increase in
pain free walking distance, in total walking distance,
in rest and post-exercise ABI and in claudication self-
assessment, as compared with patients who received
placebo. The functional improvement was greater
than the increase in ABI, which suggested that statin
effect was not solely mediated by regression of the
atheroma.
Mohler et al.26 conducted a multi-center, double-
blind, placebo-controlled, parallel group study to
evaluate the effect of 12-months treatment with ator-
vastatin (10 or 80 mg/d) on walking distance in 354
patients with lower extremity PAD and intermittent
claudication. The primary end-point of improvement
in maximal walking time was not reached, but aEur J Vasc Endovasc Surg Vol 33, February 2007
196 G. Erez and E. Leitersdorfsecondary end-point of improvement in pain free
walking time was increased by 63% in the 80 mg ator-
vastatin group, as compared with 38% in the placebo
group (p ¼ 0.025). One (of several) measure of subjec-
tive improvement in the quality of life (LOPAR ques-
tionnaire) was also found to be improved by
atorvastatin treatment. There was no improvement
in the ABI.
3. Perioperative treatment of patients with LE-PAD
The hypothesis that statin therapy has a beneficial ef-
fect on outcomes after vascular surgery is relatively
new. A single, small randomized trial has shown
that peri-operative atorvastatin treatment reduced
by 3-fold the number of cardiovascular events occur-
ring within 6 months of surgery.27 This finding has
received support from a few retrospective studies
reporting some benefit for pre-operative statin treat-
ment, and their results are summarized in Table 3.
The peri-operative management of patients with pe-
ripheral arterial disease will be the subject of a later
review in this series.
Abdominal Aortic Aneurysm
Although an association between abdominal aortic
aneurysm (AAA) and atherosclerosis has been de-
scribed in many epidemiological studies, the causal
relationship between these two entities remains un-
clear. On the contrary, the emerging concept regarding
formation of AAA focuses primarily on changes in the
vascular smooth muscle cell (including over expres-
sion of matrix metalloproteinases) and inflammation,
rather than on atherosclerosis being the primary
causal initiating factor.32 The medical management
of AAA will be the topic of the last in these series of
vascular medicine reviews, but there is accumulating
evidence that statin therapy reduces cardiovascular
risk in AAA patients as well as potentially having
direct effects to slow AAA expansion rates.33,34
Clinical Recommendations
The evidence for the use of statins in patients with
carotid and lower limb atherosclerosis as well as for
patients with abdominal aortic aneurysms leads to
the clinical recommendations shown in Fig. 1.
Arterial Stiffness
Increased arterial stiffness, the clinical correlate of
which is increased pulse pressure, is an independent
predictor of cardiovascular events.35 Increased arterialEur J Vasc Endovasc Surg Vol 33, February 2007T
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197Statin Treatment in Peripheral Arterial Disease1. All patients presenting with peripheral arterial disease (cerebrovascular, lower
extremity, abdominal aortic aneurysm) should be considered at high risk for
coronary artery disease (CAD equivalent).
2. A fasting plasma lipid profile (including total cholesterol, LDL-cholesterol,
HDL-cholesterol and triglycerides) should be obtained for all patients.
3. Statin therapy should be initiated for all patients with PAD, if no contra-
indication exists.
4. The target level for fasting plasma LDL-cholesterol should be less than
100mg/dl (2.58mmol/L). A secondary target of non-HDL cholesterol below
130mg/dl (3.35mmol/L) applies to patients with elevated triglycerides.
Fig. 1. Clinical recommendations.stiffness is seen with advancing age, supposedly due
to degeneration of elastic fibers in the vascular wall,
with a relative increase in the collagen, non-elastic
component.36
Hypercholesterolemia, alone or when combined
with hypertension, results in an increase in arterial
stiffness.37,38 The effects of statins on arterial stiffness
have been studied in several small non-randomized
trials, using different vascular beds and different mea-
sures for the assessment of arterial stiffness. Their
findings are somewhat conflicting, and are summa-
rized in Table 4.
Tomochika et al.38 aimed to assess the morphologi-
cal and functional characteristics of the thoracic aorta
in familial hypercholesterolaemia (FH) patients and in
normal controls. However, they also report the results
of 13-month treatmentwith diet, pravastatin (20mg/d)
and probucol (1000 mg/d) in a non-randomized un-
controlled fashion, in 12 of 22 FH patients. They found
a significant correlation between reduction of serum
total cholesterol and LDL-cholesterol levels and reduc-
tion in the calculated stiffness parameter.
Smilde et al.39 studied 45 patients with familial
hypercholesterolemia (FH), who were treated with
40e80 mg/d of simvastatin or atorvastatin. They
report a significant increase in the distensibility
coefficient and in the compliance coefficient, both
measures of arterial stiffness, in the common femoral
but not in the common carotid artery, after 1 year of
statin therapy.
Leibovitz et al.40 studied 17 patients with severe
hypercholesterolemia (LDL-C above 170 mg/dL),
and measured arterial compliance. After 4 months of
treatment with atorvastatin (mean dose 16 mg/d),
the large artery elasticity index showed a tendency
to increase, but this was not clinically significant.
The small artery elasticity index increased by21% (p< 0.01) after treatment, as compared with
pre-treatment values. Systolic and diastolic blood
pressures also decreased slightly but significantly.
Shige et al.41 designed a small prospective double-
blind cross-over study with 20/40 mg simvastatin,
in order to explore the relationship between lowering
cholesterol levels and arterial compliance. They exam-
ined systemic arterial compliance (SAC), as well as re-
gional pulse-wave velocity (PWV) over the trunk
(aorto-femoral circulation) and the leg (femoral-distal
tibial). They found that despite a significant LDL-C
lowering effect achieved by treatment with simvasta-
tin, SAC and central PWV did not change. However,
peripheral PWV was higher, indicating better compli-
ance, after treatment with simvastatin. These findings
indicate that lipid lowering by simvastatin improves
compliance of smaller peripheral arteries, but not
the compliance of large central arteries. This study
did not include any clinical end-points.
Giannattasio et al.42 studied the functional properties
of the radial artery before and after induced ischemia in
13 normotensive FH patients and 10 normotensive
non-FH controls. In 7 FH patients, they have repeated
those studies after 6 and 24 months of treatment with
simvastatin 40 mg/d. In those patients, maximal fore-
arm blood flow was significantly increased and mini-
mal forearm vascular resistance was significantly
reduced after 6 months of therapy. These changes be-
came more pronounced after 24 months. Pre-ischemic
radial artery distensibility and compliance did not
change after 6 months, but significantly increased after
24 months of statin therapy. Post-ischemic values
were slightly increased, but these results did not reach
statistical significance.
Ferrier et al.43 studied 22 patients with isolated
systolic hypertension and normocholesterolemia, in
a double-blind, placebo-controlled, cross-over studyEur J Vasc Endovasc Surg Vol 33, February 2007
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2007Table 4. The effect of statin therapy on arterial stiffness
Study type No. of
participants
Patient characteristics Type of intervention Follow-up
time
Measure for
arterial stiffness
Non-randomized,
uncontrolled
12 Familial
hypercholesterolemia
Diet, pravastatin
and probucol
13 months b, derived from
dimensional cha
in descending ao
visualized by TE
and brachial arte
cuff-measured p
Prospective,
non-randomized
7 Normotensive
familial
hypercholesterolemia
40 mg simvastatin 24 months Pre- and post-isc
radial artery com
and distensibilit
maximal forearm
bloodflow and
minimal forearm
vascular resistan
Prospective,
non-randomized
45 Familial
hypercholesterolemia
40e80 mg/d
simvastatin or
atorvastatin
One year Distensibility co
(DC) and compl
coefficient (CC)
and CFA
Prospective,
non-randomized
17 LDL-C> 170 mg/dL Atorvastatin, mean
dose 16 mg/d
4 months Large and small
elasticity indices
Prospective,
double-blind,
cross-over
20 Hypercholesterolemia 20e40 mg
simvastatin
8 weeks Systemic arterial
compliance (SAC
regional pulse w
velocity (PWV):
aorto-femoral an
femoral-distal tib
Double-blind,
placebo-controlled,
cross-over
22 Isolated systolic
hypertension,
normocholesterolemia
80 mg atorvastatin 6 months Systemic arterial
compliance
Abbreviations: TEE¼ trans esophageal echocardiography, TC¼ total cholesterol, LDL-C¼ low density lipoprotein ch
artery.
199Statin Treatment in Peripheral Arterial Diseasewith 80 mg atorvastatin. They have found that 3
months of atorvastatin treatment resulted in a signifi-
cant 24% increase in systemic arterial compliance.
Systolic, diastolic and mean blood pressures have all
significantly decreased by 2e6 mmHg.
Taken together, these studies imply that statin ther-
apy may have a beneficial effect on arterial stiffness in
hypercholesterolemic, and maybe also in normocho-
lesterolemic patients. However, the nature of this
effect, its extent and location should all be further
assessed by larger, randomized controlled studies.
Mechanism of Action of Statins
As implied by their name, HMG-CoA reductase in-
hibitors (‘statins’) have been primarily designed to
lower serum cholesterol levels by inhibiting the rate
limiting step in cholesterol biosynthesis. This inhibi-
tion results in up-regulation of the LDL receptor on
the hepatocyte membrane, and hence in increased up-
take of LDL particles from the plasma. This choles-
terol lowering effect is expected to result in some
clinical benefit only after months of treatment.
The finding that statins have an immediate bene-
ficial effect on cardiovascular outcome implies that
at least some of their effect is otherwise mediated.
There is now much evidence that statins exert addi-
tional, pleiotropic and beneficial effects on atheroscle-
rotic events by generating improvement in
endothelial function, stabilization of atherosclerotic
plaques, inhibition of platelet aggregation, inhibition
of inflammation, inhibition of smooth muscle cell
proliferation, antioxidant effects and accelerated
angiogenesis.44
Summary and Recommendations
Peripheral arterial disease is a definite marker for dif-
fuse atherosclerosis and is associated with significant
morbidity and mortality. It has long been acknowl-
edged as a coronary artery disease equivalent in terms
of the risk it carries and therefore the recommenda-
tions for treatment. Nevertheless, patients suffering
from PAD remain undertreated as compared with
their CAD counterparts and significantly under-
treated with respect to published guidelines. The rea-
sons for this may include (among others) patient and
physician underestimation of the actual risk, treating
physicians (e.g. vascular surgeons and intervention-
ists) being less familiar with these drugs, or lack of
awareness to published guidelines.Although only a small number of studies, most of
which were small and retrospective, have specifically
addressed the question of statin therapy in different
aspects of PAD treatment, the vast majority have
proved at least some benefit for statin use.
Taking all this information together, it is clear that
PAD patients should receive statin therapy as an inte-
gral part of their treatment plan, and should be fully
advised as to the known benefits and risks associated
with these drugs. The best regimen for statin treat-
ment, in terms of specific drug or dose, remains to
be evaluated by prospective randomized trials.
Furthermore, several other lipid-modifying drugs
are currently undergoing clinical trials, including
squalene-synthase inhibitors and cholesteryl-ester
transfer protein (CETP) inhibitors. If any of these are
proven beneficial for prevention of coronary out-
comes, clinical trials in PAD patients should not be
neglected.
Box 1.
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